open-label
Xenon in the treatment of panic disorder: an open label study
10
An open label study of aripiprazole for methamphetamine induced psychosis
9
Baclofen as relapse prevention in the treatment of Gamma Hydroxybutyrate (GHB) dependence: an open label study
8
The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open label study
8
The Effect of Curcumin on Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An Open Label Study
11
EVALUATION OF ANTIUROLITHIC HERBAL FORMULA FOR UROLITHIASIS: A RANDOMIZED OPEN LABEL CLINICAL STUDY
6
Treatment of alcohol dependence with low dose topiramate: an open label controlled study
7
Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial
9
A prospective, open label, 24 week trial of methylcobalamin in the treatment of diabetic polyneuropathy
5
Rapid Visible Improvements in Onychomycosis: An Open Label Clinical Investigation of Kerasal NailTM
10
Treatment of mucocutaneous manifestations in Behçet’s disease with anakinra: a pilot open label study
7
A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis
28
Acupuncture for patients with mild hypertension: study protocol of an open label multicenter randomized controlled trial
10
Olmesartan for non alcoholic steatohepatitis complicated with hypertension: An open label study
6
Duloxetine in the treatment of major depressive disorder: an open label study
11
A prospective, open label, pilot study to evaluate the role of sucralfate in the management of pressure ulcers
114
Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP study
23
A Prospective, Randomized, Open Label, Comparative Study of Resveratrol as an Add on Therapy in Systemic Hypertension
117
NeuralClassifier: An Open source Neural Hierarchical Multi label Text Classification Toolkit
6
Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis : results from a phase IIa open‐label trial and subsequent phase III open‐label extension
13